Citations

Clear

97 citation(s) found for "Szabo, L".

Targeting NF-κB prevents Schwann cell reprogramming and plexiform neurofibroma initiation in mouse model of Nf1
Ravindran, Ramya , Youn, Eui-Kyung, Kedei, Noémi , Choi, Kwangmin , Volz, Avery, Dombi, Eva , Pundavela, Jay , Kim, MiOk, Spinner, Robert J. , Szabo, Sara , Largaespada, David A. , Shern, Jack F. , Ratner, Nancy

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.11.04.764357 Get It

Plexiform neurofibromas arise in approximately half of all individuals with Neurofibromatosis Type I (NF1). Genetic lesions apart from NF1 pathogenic variants are not present in NF1 mutant Schwann cells, suggesting that tumorigenesis may instead require cellular rewiring. To identify putatively re-wired tumor cells, we used multiplex imaging and flow cytometry to delineate markers that distinguish tumor Schwann cell from non-tumor Schwann cells. We identified tumor Schwann cells as CD44+;CD49f+ cells that show increased transcription of epithelial to mesenchymal plasticity (EMP)- associated genes. CD44+;CD49f+ expression was induced by treating Nf1-/- Schwann cells with stressors or by direct NF-κB pathway activation via IKK2; treated Schwann cells increased secretion of NF-κB targets and immune cell chemoattractants CCL2 and CCL3. In established tumors, MEK inhibition plus NF-κB blockade diminished tumor cell proliferation, tumor Schwann cells, immune cell populations, tumor cytokines and tumor number. Notably, transient single agent NF-κB pathway blockade was sufficient to significantly delay tumor formation in mice. Thus, Nf1 loss in Schwann cells is followed by NF-κB activation and cellular reprogramming that drives tumor initiation and targeting NF-κB activation can reduce NF1-deficient tumor formation.
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy
Fradin, James J. , Rein, Lisa, Szabo, Aniko, Carlson, Karen-Sue, Badar, Talha, Holden, Troy, Shah, Shiv , Im, Annie, Patel, Anand , Atallah, E., Patel, Anand , Rein, Lisa , Aniko, Szabo, Carlson, Karen , Badar, Talha , Im, Annie , Atallah, Ehab

Mayo Clinic

Leukemia & Lymphoma | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1080/10428194.2026.2684259 | PMID 42281276 Get It

Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients With Severe Alcohol-Associated Hepatitis
Ventura-Cots, Meritxell, Clemente, Ana, Alvarado-Tapias, Edilmar, Ravi, Sujan, Cuyàs, Berta , Tanguy, M, Poca, Maria, Jäger, Marion , Arteel, Gavin E. , Villagrasa, Ares, Aguilar-Amorós, Anna, Argemí, Josepmaria , Abraldes, Juan G., Bosques, Francisco, Brown, R, Garcia-Taso, Guadalupe, Genesca, Juan, Schanbl, Bernd, Mathurin, P., Louvet, Alexander, Lucey, Michael R., Shawcross, Debbie L., Verna, Elisabeth, Dasarathy, S, Tu, Wanzhu, Kamath, Patrick S, Chalasani, Naga P, McClain, Craig J, Szabo, Gyongyi, Tang, Qing, Barton, Bruce, Nagy, Laura E. , Shah, Vijay H, Sanyal, Arun J, Singal, Ashwani K, Soriano, Germà, Rautou, Pierre Emmanuel, Shawcross, Debbie L. , Ventura Cots, Meritxell , Bataller, Ramon A , Shawcross, Debbie Lindsay , Cuyas, Berta , Ventura‐Cots, Meritxell , Alvarado‐Tápias, Edilmar , Ravi, Sujan, Tanguy, Marion , Poca, María , Fernández‐Carrillo, Carlos , Villagrasa, Ares , Abraldeṣ, Juan G. , Genescà, Joan , Mathurin, Philippe , Lucey, Michael R., Gawrieh, Samer , Tu, Wanzhu , Kamath, Patrick S. , Chalasani, Naga , McClain, Craig J. , Tang, Qing , Shah, Vijay H. , Sanyal, Arun J. , Mitchell, Mack , Singal, Ashwani K. , Rautou, Pierre-Emmanuel

Mayo Clinic

Clinical and Translational Gastroenterology | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ctg.0000000000001053 | PMID 42235929 Get It

INTRODUCTION: Alcohol-associated hepatitis (AH) is a severe condition with high short-term mortality. Identifying key predictors of poor outcomes is critical for guiding therapeutic strategies. Mean arterial pressure (MAP), a key determinant of tissue perfusion and systemic hemodynamics, may play a pivotal role in prognosis. METHODS: We analyzed a multicenter, prospective cohort of 323 patients hospitalized with AH, with validation in an independent cohort of 290 patients. Survival was evaluated using Kaplan-Meier curves and compared with the log-rank (Mantel-Cox) test. Cox proportional hazards models were used to estimate hazard ratios for mortality, adjusted for Model for end stage liver disease score. Mechanistic insights were explored through assessment of cardiovascular biomarkers. RESULTS: A baseline MAP <80 mm Hg was associated with significantly higher mortality at both 28 days (27.3% vs 8.0%) and 90 days (40.3% vs 15.6%; P < 0.001 for both). This association persisted after adjusting for Model for end stage liver disease score, age, and baseline hepatic encephalopathy. The incidence of infections during follow-up was similar across MAP groups (27.6% vs 22.8%), but acute kidney injury occurred more frequently in the MAP <80 mm Hg group (62% vs 38%, P < 0.001). In the validation cohort, patients with MAP <80 mm Hg also demonstrated significantly lower 28-day transplant-free survival. Although B-type natriuretic peptide and plasma renin levels were altered in patients with AH, they did not correlate with MAP values. DISCUSSION: A baseline MAP <80 mm Hg is an independent predictor of short-term and mid-term mortality in patients with AH. Strategies aimed at restoring hemodynamic stability may improve outcomes in this high-risk population.
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-
Bansal, Ajay, Stoffel, Elena M., Lim, Ramona , Burke, Carol, Hall, Michael J., Singh, Aparajita , Boardman, Lisa A., Samadder, Niloy Jewel, Ballestar, Veroushka, Muller, Charles, Scott, Aaron J. , Xu, Yanfei , Eickhoff, Jens, Meredith, Hyun, Aquila, Lanni , Szabó, Éva , Della’Zanna, Gary , Bengtson, Lisa, Schlom, Jeffrey, Donahue, Renee N., Horn, Lucas A., Palena, Claudia, Gulley, James L., Samaddar, Sohini, Moore, Dennis F., Sharma, Parth, Madan, Rashna , Hurley, Karen, Soon‐Shiong, Patrick , Gabitzsch, Elizabeth, Sender, Lennie, Brenner, Dean, Schuetze, Scott, Djuric, Zora, Barroilhet, L. E., Thompson, Patricia, Bauman, Julie, Khan, Seema, Vilar, Eduardo, Szabo, Eva , Stoffel, Elena M. , Stanich, Peter P. , Patel, Swati , Burke, Carol A. , Hall, Michael J. , Muller, Charles , Benante, Kelly A. , Eickhoff, Jens C. , Zaborek, Jen , Umar, Asad , Richmond, Ellen S. , Schlom, Jeffrey , Donahue, Renee Nicole , Toney, Nicole J. , Palena, Claudia , Gulley, James L , Moore, Dennis F., Djurić, Zora , Barroilhet, Lisa , Vilar, Eduardo

Mayo Clinic

Frontiers in Immunology | May 19, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1809281 | PMID 42238576 Get It

Introduction Lynch syndrome (LS) is a hereditary cancer syndrome that increases risk for colorectal and other cancers. We hypothesize that vaccines against tumor-associated antigens CEA, MUC1, and brachyury, simultaneously delivered in an adenovirus serotype-5 vector (Tri-Ad5) combined with the immune-enhancing IL-15 receptor superagonist nogapendekin-alfa-inbakicept (NAI) will reduce the incidence of colorectal neoplasms in LS carriers. Methods In this ongoing phase IIB double-blind placebo-controlled trial, two open-label safety phases (SPs) assessed safety of Tri-Ad5 alone (SP1, n=10) and with added NAI (SP2, n=10). A randomized controlled trial (RCT) follows the SPs. After baseline colonoscopy, vaccine dosing occurs at weeks 0, 4 and 8; Tri-Ad5 alone in SP1 and Tri-Ad5 plus NAI in SP2, with identical boosters at Week 52. The RCT phase participants (n=138) were randomized to receive Tri-Ad5 plus NAI or placebo. All participants complete colonoscopy at Weeks 52 and 104 for assessment of the primary endpoint: cumulative colorectal neoplasm incidence. Secondary endpoints include safety, tolerability, and immunogenicity. Results All 20 SP participants (median age 57.5 (range 42–75), 70% female, 15% minority) received all prime and booster series. SP1 participants reported 139 adverse events (AEs) and SP2 participants reported 178. AEs were predominantly grade 1; no treatment-related serious adverse events (SAEs) occurred. The most common treatment-related AEs were reactogenic events including grade 3 rash (without skin necrosis or breakdown) at NAI injection site (100% of SP2 participants). The RCT phase (n=138) recently completed accrual. Discussion In LS carriers without active cancer, the combination of Tri-Ad5 + NAI was well-tolerated; the RCT phase is ongoing. Clinical Trial Registration https://clinicaltrials.gov/study/ , identifier NCT05419011.
Assessment of early return to drinking in surviving patients with alcohol‐associated hepatitis
Cotter, Thomas G., Mitchell, M. Ellen, Tu, Wanzhu , Tang, Qing, Yu, Yunpeng, McClain, Craig J., Bataller, Rebeca, Chalasani, Naga, Shah, Vijay H. , Sanyal, Arun J., Szabo, Gyongyi, Dasarathy, Srinivasan, Cotter, T G , Mitchell, Mack C., Tu, Wanzhu , Tang, Qing , Gawrieh, Samer , McClain, Craig J. , Bataller, Ramon, Chalasani, Naga , Sanyal, Arun J.

Mayo Clinic

Alcohol, Clinical and Experimental Research | April 6, 2026 | Volume: 50 | Issue: 4 | Pages: No page available

10.1111/acer.70263 | PMID 41941058 Get It

Abstract Background Recurrent alcohol use is a major determinant of liver‐related outcomes in patients recovering from alcohol‐associated hepatitis (AH). However, the timing and predictors of return to drinking (RTD) are not well‐studied. Methods We analyzed alcohol use among patients with AH enrolled in two AlcHepNet multicenter studies: a Phase 2b randomized controlled trial and a prospective observational study. TimeLine FollowBack (TLFB) assessed drinking at each visit. RTD was defined as any alcohol use since the previous visit. The cumulative incidence of RTD was evaluated using the Fine–Gray method, with death as a competing risk. Factors associated with RTD were evaluated using univariate and multivariate Cox regression. Results Among 518 patients alive at Day 28, RTD occurred in 7.7%, 21.7%, and 30.8% at 30, 90, and 180 days, respectively. Patients with moderate AH (mAH, MELD 11–19, n = 103) had a higher RTD incidence at 180 days than those with severe AH (sAH, MELD ≥20, n = 415) (44.3% vs. 27.5%; p = 0.01). RTD was associated with higher AUDIT scores, family history of alcohol use disorder (AUD), lower education, greater alcohol use at baseline, lower MELD scores, and less ascites (all p ≤ 0.01). In multivariable analysis, >20 drinking days in the prior month was associated with increased risk of RTD (HR: 3.46, 95% CI: 2.21–5.39), whereas college education or higher was protective (HR: 0.53, 95% CI: 0.32–0.88). Conclusion RTD occurred in 22% of AH patients within 90 days postrecovery, highlighting the need for early AUD interventions. Frequent drinking days at baseline and lower education were strongly linked to early RTD.
An automated plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease
Levin, Scott , Engel, Brian, Carlson, Corey M., Hinson, Jeremiah, Holland, Mark D. , Figdore, Dan, Tiers, Laurent, Bhatt, Kinal , Schlichtmann, Ben, Hoffmann, Katie, Bae, Ye Eun, Szabo, Miklos, Um, Yoo Hyun , Algeciras-Schimnich, Alicia, Hinson, Jeremiah S. , Figdore, Daniel J. , Lim, Hyun Kook , Schlichtmann, Benjamin W. , Lehmann, Sylvain , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | March 8, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71143 | PMID 41789706 Get It

Abstract INTRODUCTION Determining apolipoprotein E ( APOE ) ε4 allele status, a key genetic risk factor for Alzheimer's disease (AD), requires molecular genotyping infrastructure not widely accessible beyond specialized centers. METHODS A fully automated high‐throughput apoE E4 proteotyping immunoassay was evaluated for clinical performance (460 participants across three cohorts) and analytical validity. Concordance with polymerase chain reaction (PCR)‐based genotyping and measures of analytical validity were reported. RESULTS The apoE E4 immunoassay demonstrated 99.6% (95% confidence interval [CI]: 98.4% to 99.9%) concordance with PCR‐based APOE ε4 genotype results across the pooled clinical cohort; 100.0% (95% CI: 97.1% to 100.0%) in those with AD ( N = 127) and 99.4% (95% CI: 97.8% to 99.8%) in those without AD (333). The assay met analytical validity criteria for E4 isoform specificity, interference, precision, and stability. DISCUSSION The apoE E4 immunoassay demonstrated high concordance with PCR‐based genotyping and robust analytical validity, offering an accessible alternative for APOE ε4 zygosity assessment. Highlights A novel high‐throughput plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification was developed and evaluated for clinical performance and analytical validity. The apoE E4 immunoassay demonstrated high concordance (99.6%) with PCR‐based APOE ε4 genotyping across a diverse international cohort, and a robust analytical profile. An apoE E4 immunoassay may offer a more cost‐effective and accessible alternative to DNA genotyping approaches currently used for AD risk evaluation and anti‐amyloid treatment decisions.
Age, sex and ethnicity-stratified myocardial strain reference ranges from the healthy hearts consortium
Salatzki, Janek , Condurache, D G, Roy, R, Szabo, L, Akilu, Tesfamariam, Salih, A M, Chadalavada, S, Leiner, Tim, Chin, C W L, Barison, A, Döerr, Marcus, Friedrich, M G, Andre, F, Petersen, S E, Raisi-Estabragh, Z, Condurache, Dorina-Gabriela , Chadalavada, Sucharitha , Leiner, Tim , Dörr, Marcus , Friedrich, Matthias G. , Andre, F, Raisi‐Estabragh, Zahra

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.226 Get It

Abstract Background Myocardial feature-tracking (FT) strain from cardiovascular magnetic resonance (CMR) has incremental prognostic value beyond traditional imaging biomarkers. Clinical use is limited by the absence of population-specific healthy reference ranges. This study provides age-, sex-, and ethnicity-specific reference ranges for CMR-derived FT strain from the Healthy Hearts Consortium (HHC). Methods The HHC is an international collaboration comprising CMR scans from 9,088 verified healthy adults across six centres, covering the entire adult age spectrum and with diverse ethnic background. Standardised CMR acquisition protocols were used. Image analysis was performed by two experienced readers following pre-specified standard operating procedures and using two commercially available software platforms (cvi42®, Circle Cardiovascular Imaging Inc.; suiteHEART®, Neosoft LLC). The following metrics were extracted: i) global FT strain metrics from both ventricles (longitudinal, circumferential, and radial) and both atria (longitudinal); ii) strain rate; iii) Mitral/Tricuspid annular plane systolic excursion (MAPSE, TAPSE); iv) rapid strain (long-axis, junctional strain) from the left ventricle and both atria. Quality control included visual inspection of all images and the removal of biologically non-sensical values and extreme statistical outliers. Reference ranges were calculated by age group (deciles: 20-80 years), sex (male/female), and ethnicity (White, Black, Chinese, South Asian, Mixed/Other) using the 95% prediction interval method. Technical variations due to scanner vendor, software platform, and field strength (1.5T vs. 3.0T), were analysed. Results The study included 4,452 men (49%) and 4,636 women (51%). Ages ranged from 18 to 83 (mean 61±13) years. The sample included diverse ethnic backgrounds [White (81.7%), South Asian (5.6%), Mixed/Other (5.3%), Black (3.7%), and Chinese (3.7%)]. Women demonstrated significantly higher absolute strain values than men across. Absolute myocardial strain values were higher in younger age groups and lower in older age groups, most notably in left global circumferential and longitudinal strain. Ethnic differences in strain were most pronounced between White and Black as well as between White and Chinese individuals regarding left and right ventricular strain values, while left and right atrial strain values as well as rapid strain values, were similar across ethnic groups. Conclusion This study provides comprehensive, population-specific reference ranges for FT-CMR-derived myocardial strain, addressing a clinical knowledge gap. These findings inform clinical interpretation, improving diagnostic accuracy and risk stratification in different populations. This work represents a significant step towards a broader clinical implementation of myocardial strain analysis in routine cardiovascular care, ensuring more accurate classification of findings across varying demographic groups.
Multicenter cardiovascular magnetic resonance reference ranges and severity grading for ventricular and atrial measurements: insights from the healthy hearts consortium
Szabo, L E, McCracken, Celeste , Condurache, D G, Aquaro, G D, Andre, F, Sucha, D, Harvey, N C, Leiner, Tim, Chin, C W L, Friedrich, M G, Barison, A, Dörr, M, Raisi-Estabragh, Z, Petersen, S E, Condurache, Dorina-Gabriela , Bulow, R, Aquaro, Giovanni Donato , Andre, F, Suchá, Dominika , Leiner, Tim , Friedrich, Matthias G. , Dörr, Marcus , Raisi‐Estabragh, Zahra , Petersen, S E

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.219 Get It

Abstract Introduction Cardiovascular magnetic resonance (CMR) imaging enables precise, non-invasive assessment of cardiac structure and function, yet the clinical utility of CMR metrics is limited by the lack of comprehensive, population-specific reference values. By directly reanalyzing data from a large, multi-ethnic cohort rather than relying solely on pooled literature, could enable the establishment of standardized reference ranges and severity grading thresholds. Aim To provide comprehensive, age-, sex-, and ethnicity-stratified CMR reference ranges and severity grading thresholds for key ventricular and atrial parameters. Methods We analyzed over 9,000 CMR scans from the Healthy Hearts Consortium (HHC), comprising six international cohorts. All individuals were free from overt cardiovascular disease and major comorbidities, ensuring a verified healthy sample. Two automated segmentation software solutions—cvi42 (Circle Cardiovascular Imaging) and suiteHEART (Neosoft)—were used to quantify left and right ventricular volumes, myocardial mass, and atrial volumes in standard cine stacks. All endorsed segmentation modes were applied. Quality control protocol combined expert visual review and statistical outlier analysis. We derived 95% prediction intervals (PI) to define the normal range, with additional severity thresholds for mild (95–99.73% PI), moderate (99.73–99.99% PI), and severe (&gt;99.99% PI) deviation from the reference range. Results The final dataset comprised of 9,059 verified healthy adults aged 18–83 years (mean 61 ± 13 years), with a near-equal sex distribution (51% women). Demographics included White (81.6%), South Asian (5.6%), Mixed/Other (5.3%), Black (3.8%), and Chinese (3.7%) participants. Results demonstrated that sex, age, and ethnicity strongly influenced cardiac indices. Men had higher indexed LV and RV volumes and greater myocardial mass than women. Black participants presented the highest indexed LV myocardial mass across age groups, whereas Chinese participants had comparatively lower myocardial mass values (Figure 1). In contrast, atrial volumes remained relatively stable across age categories. Comparative analysis showed minor differences between the two software tools, particularly for atrial parameters; however, derived ejection fractions remained consistent. We established age-, sex-, and ethnicity-stratified reference ranges for key CMR parameters. To facilitate clinical interpretation, we defined severity thresholds corresponding to mild, moderate, and severe abnormalities. Conclusion This large-scale, international effort addresses prior limitations in CMR interpretation by offering robust, contemporary reference ranges and severity grading applicable to diverse populations and imaging protocols. Our severity grading thresholds support consistency in clinical reporting and decision-making, enabling clearer identification of early subclinical changes and more accurate monitoring of disease progression.Subset of CMR value ranges in females
Age, sex and ethnicity-stratified myocardial feature tracking strain reference ranges
Salatzki, Janek , Condurache, D G, Roy, R, Szabo, L, Akilu, Tesfamariam, Salih, A, Chadalavada, S, Leiner, Tim, Chin, C W L, Barison, A, Döerr, Marcus, Friedrich, M G, Andre, F, Petersen, S E, Raisi-Estabragh, Z, Condurache, Dorina-Gabriela , Roy, R, Szabo, L, Chadalavada, Sucharitha , Leiner, Tim , Chin, C W L, Dörr, Marcus , Friedrich, Matthias G. , Petersen, Steffen, Raisi‐Estabragh, Zahra

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 30, 2026 | Volume: 27 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeaf367.409 Get It

Abstract Background Myocardial strain derived from cardiovascular magnetic resonance (CMR) using feature tracking (FT) offers incremental prognostic value beyond traditional imaging markers. However, its broader clinical application is hindered by the lack of population-specific reference ranges. This study establishes age-, sex-, and ethnicity-specific normative data for FT-CMR-derived myocardial strain metrics from the Healthy Hearts Consortium (HHC). Methods The HHC is a large, international, multicohort initiative comprising CMR data from 9,088 rigorously screened healthy adults across six centers. The cohort spans the full adult age range and includes greater ethnic diversity than any comparable dataset. CMR scans were acquired using standardized protocols. Image analysis followed pre-specified standard operating procedures and was performed by two experienced readers using two commercial platforms (CVI42®, Circle Cardiovascular Imaging; suiteHEART®, Neosoft). Metrics extracted included: (i) global longitudinal, circumferential, and radial FT strain for both ventricles and atria; (ii) strain rate; (iii) annular plane systolic excursion (MAPSE, TAPSE); and (iv) rapid strain metrics (long-axis, junctional strain) for the left ventricle and atria. Comprehensive quality control involved visual review and exclusion of biologically implausible or extreme outlier values. Reference ranges were calculated using the 95% prediction interval method, stratified by age deciles (20–80 years), sex, and ethnicity (White, Black, Chinese, South Asian, Mixed/Other). The impact of technical factors—scanner vendor, field strength (1.5T vs 3.0T), and software platform—was also assessed. Results The study included 4,452 men (49%) and 4,636 women (51%), aged 18 to 83 years (mean 61 ± 13). The cohort was ethnically diverse: White (81.7%), South Asian (5.6%), Mixed/Other (5.3%), Black (3.7%), and Chinese (3.7%). Women consistently exhibited higher absolute strain values than men. A clear age-related decline in strain was observed, particularly in left ventricular global circumferential and longitudinal strain. Ethnic differences were most pronounced between White and Black, and White and Chinese individuals for RV and LV strain metrics; in contrast, RA, LA, and rapid strain metrics showed minimal ethnic variation. Conclusion This study delivers the most comprehensive age-, sex-, and ethnicity-specific reference ranges to date for FT-CMR-derived myocardial strain. These normative values support improved clinical interpretation, aiding diagnosis and risk stratification in diverse populations. The findings mark a pivotal advancement towards the routine integration of myocardial strain assessment in cardiovascular imaging practice.
Inflammation rewires the enteric nervous system through neurogenic monocyte recruitment
Kurapati, Sravya , Shin, Changsik , Szabo, Krisztina , Liu, Yu , Ashraf, Azree Zaffran, Koscsó, Balázs , Dash, Chinmayee , Kruckow, Katherine L. , Navarro, L Guerrero, Clark, Amanda M. , Saha, Monalee , Nagaraj, Sushma , Wang, Wenhui , Zhu, Jun , Thomson, Travis , Shulzhenko, Natalia , Morgun, Andrey , Pasricha, Pankaj J. , Peters, Lauren A., Bogunovic, Milena , Ashraf, Azree Z , Navarro, Leonardo E , Brown, Kevin , Thomson, Travis , Shulzhenko, Natalia , Morgun, Andrey , Baer, Christina E , Srinivasan, Shanthi , Kulkarni, Subhash , Pasricha, Pankaj Jay , Peters, Lauren A , Bogunovic, Milena , Clark, Amanda M. , Kulkarni, Subhash

Mayo Clinic

Journal of Experimental Medicine | December 20, 2025 | Volume: 223 | Issue: 4 | Pages: No page available

10.1084/jem.20251761 | PMID 41774078 Get It

Proper organization of the enteric nervous system (ENS) is critical for normal gastrointestinal (GI) physiology. Inflammatory bowel disease (IBD) disrupts key GI functions, including bowel motility. However, in many IBD patients, motility disorders persist even during remission, suggesting an irreversible ENS defect secondary to IBD. Here, we show that postinflammatory GI motility dysfunction arises from structural remodeling of the ENS, driven by a combination of neuronal loss and neurogenesis. During mucosal inflammation, enteric neurons upregulate CCL2 expression, facilitating the recruitment of monocytes into the myenteric plexus within the intestinal muscle. Monocyte-derived macrophages infiltrate the myenteric ganglia, contributing to excessive ENS remodeling and postinflammatory motility dysfunction. This neuroimmune axis is counterbalanced by a hypoxia-induced stress response in enteric neurons mediated by HIF1α. Enhancing the neuron-intrinsic hypoxia pathway limits ENS remodeling and preserves motility. In summary, this study presents a mechanistic model of postinflammatory GI motility dysfunction and proposes a therapeutic strategy to maintain ENS integrity and function during inflammation.